Neos Therapeutics to Host First Quarter 2020 Financial and Operating Results Conference Call on May 11th, 2020

Rhea-AI Summary

Neos Therapeutics, a pharmaceutical company focused on central nervous system products, will report its first quarter 2020 financial results on May 11, 2020, after U.S. markets close. A conference call and audio webcast will follow at 5:00 p.m. ET, where management will discuss the results and provide updates. Interested parties can join the call via phone or through a live webcast on the company's Investor Relations page. Neos is known for its innovative microparticle delivery technology, offering products for ADHD treatment, including Adzenys XR-ODT and Cotempla XR-ODT.

DALLAS and FORT WORTH, Texas, May 04, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its first quarter 2020 financial results at the closing of U.S. financial markets on Monday, May 11, 2020. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 5:00 p.m. ET that same day.

The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 1099917. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/ and will be available for replay following the call for 30 days.

About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ: NEOS) is a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products. Adzenys XR-ODT^® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT^® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER^® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are three approved products utilizing the Company’s novel microparticle delivery technology. Additional information about Neos is available at www.neostx.com.

CONTACTS:

Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com

Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
sarah.mccabe@sternir.com

FAQ

What date will Neos Therapeutics report its Q1 2020 financial results?

Neos Therapeutics will report its first quarter 2020 financial results on May 11, 2020.

What time is the Neos Therapeutics conference call on May 11, 2020?

The Neos Therapeutics conference call is scheduled for 5:00 p.m. ET on May 11, 2020.

How can I access the Neos Therapeutics conference call?

The conference call can be accessed by dialing (877) 388-8985 for domestic calls or +1 (562) 912-2654 for international callers, using conference ID 1099917.

Where can I find the live audio webcast for Neos Therapeutics?

The live audio webcast for Neos Therapeutics can be found on their Investor Relations page at www.neostx.com.

What products does Neos Therapeutics focus on?

Neos Therapeutics focuses on developing and manufacturing central nervous system products, particularly for ADHD treatment.